UA84025C2 - Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS - Google Patents
Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORSInfo
- Publication number
- UA84025C2 UA84025C2 UAA200601931A UAA200601931A UA84025C2 UA 84025 C2 UA84025 C2 UA 84025C2 UA A200601931 A UAA200601931 A UA A200601931A UA A200601931 A UAA200601931 A UA A200601931A UA 84025 C2 UA84025 C2 UA 84025C2
- Authority
- UA
- Ukraine
- Prior art keywords
- heading
- ylsulfonylamino
- quinoxalin
- normal
- cck2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Structural Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49407403P | 2003-08-08 | 2003-08-08 | |
| PCT/US2004/025153 WO2005016896A1 (en) | 2003-08-08 | 2004-08-04 | 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA84025C2 true UA84025C2 (en) | 2008-09-10 |
Family
ID=34193199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200601931A UA84025C2 (en) | 2003-08-08 | 2004-08-04 | Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7288651B2 (ru) |
| EP (2) | EP1651621B1 (ru) |
| JP (2) | JP2007501842A (ru) |
| KR (1) | KR20060060007A (ru) |
| CN (2) | CN1863782A (ru) |
| AR (1) | AR045930A1 (ru) |
| AT (2) | ATE403650T1 (ru) |
| AU (2) | AU2004265312B2 (ru) |
| BR (1) | BRPI0413449A (ru) |
| CA (2) | CA2534887A1 (ru) |
| CR (1) | CR8229A (ru) |
| CY (1) | CY1106486T1 (ru) |
| DE (2) | DE602004004663T2 (ru) |
| DK (2) | DK1651621T3 (ru) |
| EA (1) | EA200600203A1 (ru) |
| EC (1) | ECSP066355A (ru) |
| ES (2) | ES2310294T3 (ru) |
| HR (1) | HRP20080559T3 (ru) |
| IL (1) | IL173591A0 (ru) |
| IS (1) | IS8280A (ru) |
| LT (1) | LT5410B (ru) |
| LV (1) | LV13453B (ru) |
| MX (2) | MXPA06001482A (ru) |
| NO (1) | NO20061122L (ru) |
| NZ (1) | NZ545030A (ru) |
| PL (2) | PL1651622T3 (ru) |
| PT (2) | PT1651621E (ru) |
| SG (1) | SG131114A1 (ru) |
| SI (2) | SI1651621T1 (ru) |
| TW (1) | TW200521120A (ru) |
| UA (1) | UA84025C2 (ru) |
| WO (2) | WO2005016897A1 (ru) |
| ZA (1) | ZA200601946B (ru) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005016897A1 (en) * | 2003-08-08 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
| WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
| WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| US7947833B2 (en) * | 2004-08-04 | 2011-05-24 | Janssen Pharmaceutica Nv | Preparation of quinoxaline compounds |
| EP1797083A1 (en) * | 2004-09-24 | 2007-06-20 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
| FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
| US8592565B2 (en) * | 2007-01-12 | 2013-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Preparation of azide-modified carbon surfaces for coupling to various species |
| EP2123644B1 (en) | 2007-03-07 | 2014-12-17 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| WO2008124518A1 (en) * | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor |
| EP2131245A3 (en) * | 2008-06-02 | 2012-08-01 | ASML Netherlands BV | Lithographic apparatus and its focus determination method |
| WO2009154754A2 (en) * | 2008-06-17 | 2009-12-23 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| WO2010118208A1 (en) * | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| CA2777108A1 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
| JP5815029B2 (ja) | 2010-07-09 | 2015-11-17 | クオンベルゲンセ プハルマセウトイカルス リミテッド | カルシウムチャネル遮断薬としてのテトラゾール化合物 |
| JP5913310B2 (ja) | 2010-07-22 | 2016-04-27 | ザフゲン,インコーポレイテッド | 三環式化合物ならびにその作製および使用方法 |
| BR112013018771A2 (pt) | 2011-01-26 | 2019-09-17 | Zafgen Inc | compostos de tetrazol e métodos para fazer e usar os mesmos |
| MX343688B (es) | 2011-05-06 | 2016-11-16 | Zafgen Inc | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. |
| CA2835261C (en) | 2011-05-06 | 2019-06-04 | Zafgen, Inc. | Partially saturated tricyclic compounds and methods of making and using same |
| US9187494B2 (en) | 2011-05-06 | 2015-11-17 | Zafgen, Inc. | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| CN104169268A (zh) | 2012-01-18 | 2014-11-26 | 扎夫根股份有限公司 | 三环砜化合物及其制备和使用方法 |
| US9359369B2 (en) | 2012-01-18 | 2016-06-07 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| PL3345899T3 (pl) * | 2012-03-01 | 2020-07-27 | Allergan, Inc. | Pochodne benzofurano-2-sulfonoamidu jako modulatory receptorów chemokin |
| CA2890344A1 (en) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds for use in the treatment and/or control of obesity |
| JP2015536981A (ja) | 2012-11-05 | 2015-12-24 | ザフゲン,インコーポレイテッド | 三環式化合物ならびにその製造および使用方法 |
| NZ707773A (en) | 2012-11-05 | 2019-05-31 | Zafgen Inc | Methods of treating liver diseases |
| JP6361168B2 (ja) * | 2013-06-17 | 2018-07-25 | Jsr株式会社 | 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物 |
| CN103524386B (zh) * | 2013-10-24 | 2016-05-18 | 江苏鼎龙科技有限公司 | 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法 |
| US10709714B2 (en) | 2013-11-22 | 2020-07-14 | Clifton Life Sciences LLC | Gastrin antagonists for treatment and prevention of osteoporosis |
| KR20170016754A (ko) * | 2015-08-04 | 2017-02-14 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN106565509A (zh) * | 2016-11-03 | 2017-04-19 | 江苏鼎龙科技有限公司 | 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法 |
| KR101894091B1 (ko) * | 2018-01-23 | 2018-08-31 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN108218806B (zh) * | 2018-04-02 | 2019-03-01 | 上海馨远医药科技有限公司 | 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法 |
| CN111285806B (zh) * | 2018-12-06 | 2022-04-15 | 中国医学科学院药物研究所 | 吡唑类化合物及其制备方法、用途和药物组合物 |
| CN116675684B (zh) * | 2023-08-02 | 2023-11-07 | 上海翰森生物医药科技有限公司 | 含炔基稠环类衍生物拮抗剂、其制备方法和应用 |
| WO2025224201A1 (en) | 2024-04-26 | 2025-10-30 | F. Hoffmann-La Roche Ag | Novel process for the synthesis of substituted morpholines and thiomorpholines |
| CN118878477B (zh) * | 2024-05-31 | 2025-09-23 | 上海馨远医药科技有限公司 | 一种手性r或s的3-甲基吗啉的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200420D0 (en) * | 1992-01-09 | 1992-02-26 | James Black Foundation The Lim | Amino acid derivatives |
| PL181782B1 (pl) * | 1993-08-10 | 2001-09-28 | Black James Foundation | Nowe zwiazki i sposób wytwarzania nowych zwiazków PL |
| EP0945445B9 (en) | 1996-12-10 | 2005-12-28 | Zeria Pharmaceutical Co., Ltd. | 1,5-benzodiazepine derivatives |
| DE10121003A1 (de) | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10121002A1 (de) | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10128331A1 (de) | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10134721A1 (de) * | 2001-07-17 | 2003-02-06 | Bayer Ag | Tetrahydrochinoxaline |
| ITTO20020674A1 (it) * | 2002-07-26 | 2004-01-26 | Rotta Research Lab | Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico |
| US6943170B2 (en) * | 2002-11-14 | 2005-09-13 | Bristol-Myers Squibb Company | N-cycloalkylglycines as HIV protease inhibitors |
| WO2005016897A1 (en) * | 2003-08-08 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
| EP1797083A1 (en) * | 2004-09-24 | 2007-06-20 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
-
2004
- 2004-08-04 WO PCT/US2004/025154 patent/WO2005016897A1/en not_active Ceased
- 2004-08-04 CN CNA200480029094XA patent/CN1863782A/zh active Pending
- 2004-08-04 AT AT04780055T patent/ATE403650T1/de not_active IP Right Cessation
- 2004-08-04 BR BRPI0413449-4A patent/BRPI0413449A/pt not_active IP Right Cessation
- 2004-08-04 EP EP04780055A patent/EP1651621B1/en not_active Expired - Lifetime
- 2004-08-04 WO PCT/US2004/025153 patent/WO2005016896A1/en not_active Ceased
- 2004-08-04 SI SI200430901T patent/SI1651621T1/sl unknown
- 2004-08-04 SI SI200430245T patent/SI1651622T1/sl unknown
- 2004-08-04 AU AU2004265312A patent/AU2004265312B2/en not_active Expired - Fee Related
- 2004-08-04 PL PL04780056T patent/PL1651622T3/pl unknown
- 2004-08-04 MX MXPA06001482A patent/MXPA06001482A/es active IP Right Grant
- 2004-08-04 JP JP2006523231A patent/JP2007501842A/ja not_active Withdrawn
- 2004-08-04 EP EP04780056A patent/EP1651622B1/en not_active Expired - Lifetime
- 2004-08-04 ES ES04780055T patent/ES2310294T3/es not_active Expired - Lifetime
- 2004-08-04 KR KR1020067002650A patent/KR20060060007A/ko not_active Withdrawn
- 2004-08-04 DK DK04780055T patent/DK1651621T3/da active
- 2004-08-04 US US10/910,983 patent/US7288651B2/en not_active Expired - Lifetime
- 2004-08-04 AT AT04780056T patent/ATE353322T1/de not_active IP Right Cessation
- 2004-08-04 NZ NZ545030A patent/NZ545030A/en unknown
- 2004-08-04 CA CA002534887A patent/CA2534887A1/en not_active Abandoned
- 2004-08-04 SG SG200701706-4A patent/SG131114A1/en unknown
- 2004-08-04 PT PT04780055T patent/PT1651621E/pt unknown
- 2004-08-04 HR HR20080559T patent/HRP20080559T3/xx unknown
- 2004-08-04 CN CNA2004800290901A patent/CN1863781A/zh active Pending
- 2004-08-04 DE DE602004004663T patent/DE602004004663T2/de not_active Expired - Lifetime
- 2004-08-04 CA CA2534885A patent/CA2534885C/en not_active Expired - Lifetime
- 2004-08-04 MX MXPA06001550A patent/MXPA06001550A/es active IP Right Grant
- 2004-08-04 AU AU2004265311A patent/AU2004265311A1/en not_active Abandoned
- 2004-08-04 DE DE602004015614T patent/DE602004015614D1/de not_active Expired - Lifetime
- 2004-08-04 DK DK04780056T patent/DK1651622T3/da active
- 2004-08-04 UA UAA200601931A patent/UA84025C2/ru unknown
- 2004-08-04 EA EA200600203A patent/EA200600203A1/ru unknown
- 2004-08-04 JP JP2006523230A patent/JP4818110B2/ja not_active Expired - Fee Related
- 2004-08-04 PT PT04780056T patent/PT1651622E/pt unknown
- 2004-08-04 PL PL04780055T patent/PL1651621T3/pl unknown
- 2004-08-04 ES ES04780056T patent/ES2281834T3/es not_active Expired - Lifetime
- 2004-08-04 US US10/910,925 patent/US7304051B2/en not_active Expired - Lifetime
- 2004-08-06 TW TW093123552A patent/TW200521120A/zh unknown
- 2004-08-06 AR ARP040102814A patent/AR045930A1/es not_active Application Discontinuation
-
2006
- 2006-01-31 IS IS8280A patent/IS8280A/is unknown
- 2006-02-07 IL IL173591A patent/IL173591A0/en unknown
- 2006-02-08 CR CR8229A patent/CR8229A/es unknown
- 2006-02-08 EC EC2006006355A patent/ECSP066355A/es unknown
- 2006-02-08 LV LVP-06-18A patent/LV13453B/en unknown
- 2006-03-07 ZA ZA200601946A patent/ZA200601946B/en unknown
- 2006-03-07 LT LT2006017A patent/LT5410B/lt not_active IP Right Cessation
- 2006-03-08 NO NO20061122A patent/NO20061122L/no not_active Application Discontinuation
-
2007
- 2007-04-04 CY CY20071100473T patent/CY1106486T1/el unknown
- 2007-12-04 US US11/950,326 patent/US7563895B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA84025C2 (en) | Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | |
| DE60112974D1 (en) | Carbolinderivate | |
| ATE461217T1 (de) | Glp-1-verbindungen | |
| SG149063A1 (en) | Use of modified cyclosporins for the treatment of hcv disorders | |
| MY135477A (en) | 2-(2,6-dichlorophenyl)-diarylimidazoles | |
| GB0223038D0 (en) | Therapeutic compounds | |
| AU2003202585A1 (en) | Disubstituted thiazolyl carboxanilides and their use as microbicides | |
| DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
| WO2003032994A3 (de) | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren | |
| TW200509892A (en) | Novel aminobenzophenone compounds | |
| AU2003281978A1 (en) | 2,5-diketopiperazines for the treatment of obesity | |
| TW200505875A (en) | Novel compounds | |
| WO2004006853A3 (en) | Treatment and prophylaxis with 4-1bb-binding agents | |
| DE60216233D1 (en) | Carbolinderivate | |
| AU2003286728A1 (en) | Compounds for the treatment of metabolic disorders | |
| AU2003258145A1 (en) | Substituted phenylindoles for the treatment of hiv | |
| MY139368A (en) | Novel cyclohexyl sulphones | |
| AU2001291725A1 (en) | Heterocyclic mutilin esters and their use as antibacterials | |
| AU2003273310A1 (en) | Substituted aminoethers for the treatment of alzheimer's disease | |
| WO2005012275A3 (en) | Benzo [1, 2, 5] thiadiazole compounds as cck2 modulators | |
| MXPA04004090A (es) | Compuestos substituidos de 1h-quinolin-2-ona. | |
| AU2003303217A1 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
| AU2003222667A1 (en) | 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases | |
| MY140194A (en) | Novel fusidic acid derivatives | |
| AU2002354698A1 (en) | Use of xaa-pro peptidases for the treatment of substance p-related disorders |